BIO Share Price

Open 7.62 Change Price %
High 7.63 1 Day -0.20 -2.63
Low 7.36 1 Week 0.00 0.00
Close 7.40 1 Month 0.00 0.00
Volume 135061 1 Year 0.00 0.00
52 Week High 208.85
52 Week Low 66.52
BIO Important Levels
Resistance 2 7.65
Resistance 1 7.55
Pivot 7.46
Support 1 7.25
Support 2 7.15
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
ALALO 0.04 -20.00%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
ACA 15.16 1.68%
More..
EPA France Top Gainers Stocks
MLROU 8.01 31.31%
VRNL 3.89 20.81%
APAM 33.78 15.72%
APAM 33.78 15.72%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
MLLEA 0.54 -44.90%
MLTMT 0.02 -33.33%
MLWEY 3.08 -26.84%
ALALO 0.04 -20.00%
MLMAT 1.11 -14.62%
OXI 0.08 -11.11%
OXI 0.08 -11.11%
GUYD 0.38 -9.52%
MLCAC 12.80 -8.51%
MLIDS 0.69 -8.00%
More..

BioAlliance Pharma (EPA: BIO)

BIO Technical Analysis 2
As on 31st Jul 2014 BIO Share Price closed @ 7.40 and we RECOMMEND Buy for LONG-TERM with Stoploss of 6.51 & Strong Sell for SHORT-TERM with Stoploss of 7.91 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for October
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bioalliancepharma.com
BIO Address
BIO
49 boulevard du G
Paris, 75015
France
Phone: 33 1 45 58 76 00
Fax: 33 1 45 58 08 81
BIO Latest News
Interactive Technical Analysis Chart BioAlliance Pharma ( BIO EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on BioAlliance Pharma
BIO Business Profile
BioAlliance Pharma SA designs, develops, and markets drugs for the treatment of cancer primarily in France. Its specialty product portfolio includes Loramyc/Oravig, a mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis in patients with head and neck cancer or AIDS; Sitavig, a mucoadhesive buccal tablet to treat recurrent herpes labialis in immunocompetent patients; and Fluriad, an H1N1 vaccine that is in preclinical trials. The company’s ophan oncology product portfolio comprises Livatag, which is in phase III clinical trial for the treatment of hepatocellular carcinoma; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trial for the prevention of chemo/radiation therapy-induced oral mucositis in patients with head and neck cancer; and AMEP/Synfoldin, a preclinical trial product for metastatic melanoma. BioAlliance Pharma SA was founded in 1997 and is based in Paris, France.